13F Holdings
中文EN

FULC Fulcrum Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1680581 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY2,752.0%
TTM net income YoY90.0%
TTM EPS YoY89.9%
Revenue 3-yr CAGR61.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-27.4%
Net margin-12.2%
FCF margin-3.1%
EBITDA margin-25.3%

Returns

ROE-4.1%
ROA-3.8%
ROIC (approx.)-8.8%
Asset turnover0.31x

Leverage & solvency

Liabilities / assets6.8%
Debt / equity0.00x
Current ratio22.63x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.23x
Accruals ratio-2.9%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$80.00M$2.81M$6.34M$19.16M
R&D expense$56.10M$63.39M$71.80M$76.78M$69.70M
SG&A expense$28.67M$36.45M$41.67M$41.69M$30.52M
Operating income-$84.77M-$21.90M-$110.66M-$112.56M-$81.05M
Income tax$0$0———
Net income-$74.88M-$9.72M-$97.33M-$109.87M-$80.85M
EBITDA-$83.38M-$20.30M-$108.49M-$110.15M-$78.54M
EPS (basic)-1.18-0.16-1.59-2.44-2.29
EPS (diluted)-1.18-0.16-1.59-2.44-2.29
Weighted avg. shares (diluted)63,35561,98461,31044,99135,361
Balance sheet
Cash & equivalents$197.53M$58.21M$25.56M$35.10M$35.41M
Current assets$357.48M$249.92M$242.20M$207.52M$226.00M
PP&E, net$2.82M$3.90M$5.22M$6.91M$7.37M
Total assets$366.28M$260.72M$257.69M$226.69M$235.00M
Current liabilities$13.05M$11.04M$13.68M$16.73M$19.20M
Total liabilities$17.28M$17.68M$22.50M$27.74M$23.46M
Shareholders' equity$349.00M$243.03M$235.19M$198.94M$211.54M
Shares outstanding66.58M53.97M61.92M52.10M40.63M
Cash flow statement
Operating cash flow-$60.06M-$2.22M-$90.97M-$97.05M-$78.48M
Capital expenditure$314,000$278,000$508,000$1.96M$1.71M
Free cash flow-$60.38M-$2.50M-$91.47M-$99.01M-$80.19M
Investing cash flow$30.72M$32.23M-$36.69M$12.41M-$129.67M
Financing cash flow$168.67M$2.75M$118.12M$84.32M$186.51M
Depreciation & amortization$1.39M$1.59M$2.17M$2.41M$2.52M
Stock-based compensation$12.47M$14.55M$14.80M$13.35M$11.07M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.